PAP
RLMD icon

Persistent Asset Partners’s Relmada Therapeutics RLMD Stock Holding History

Persistent Asset Partners’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$353K Sell
50,773
-180,350
-78% -$853K 0.13% 137
2025
Q4 		$1.12M Buy
+231,123
New +$774K 0.5% 53

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Persistent Asset Partners's RLMD Position: Q1 2026 in Review

Persistent Asset Partners reduced its Relmada Therapeutics (RLMD) stake by 78% in Q1 2026, selling an estimated $853K and leaving 50,773 shares worth $353K. The position accounts for 0.13% of the portfolio, ranked #137.

Persistent Asset Partners first reported a position in RLMD in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.12M in Q4 2025. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Persistent Asset Partners held 50,773 shares of Relmada Therapeutics worth $353K as of Q1 2026.
  • Persistent Asset Partners sold 180,350 Relmada Therapeutics shares in Q1 2026, an estimated $853K.
  • Relmada Therapeutics made up 0.13% of Persistent Asset Partners's portfolio in Q1 2026, its #137 holding.
  • Persistent Asset Partners first reported a position in Relmada Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Persistent Asset Partners's Relmada Therapeutics position peaked at $1.12M in Q4 2025.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.